Beximco Pharmaceuticals PLC. Share Price
Stocks
BXPHARMA
BD0453BXPH04
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Dhaka S.E.
27/08/2026
|
5-day change | 1st Jan Change | ||
| 145.00 BDT | +0.55% |
|
-1.02% | +42.02% |
| 06-26 | Beximco suspension lifted; M1 payment date extension | AN |
| 06-24 | Beximco Pharmaceuticals PLC. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 | CI |
| Market Cap | 64.69B 526M 453M 425M 388M 730M 50.25B 733M 5.04B 1.97B 25.36B 1.97B 1.93B 84.1B | P/E 2026 * |
7.47x | P/E 2027 * | 6.79x |
|---|---|---|---|---|---|
| Enterprise Value | 64.69B 526M 453M 425M 388M 730M 50.25B 733M 5.04B 1.97B 25.36B 1.97B 1.93B 84.1B | EV / Sales 2026 * |
1.18x | EV / Sales 2027 * | 1.06x |
| Free-Float |
85.91% | Yield 2026 * |
4.15% | Yield 2027 * | 5.31% |
| 1 day | +0.55% | ||
| 1 week | -1.02% | ||
| Current month | -3.91% | ||
| 1 month | -2.49% | ||
| 3 months | +18.85% | ||
| 6 months | +10.18% | ||
| Current year | +42.02% |
| 1 week | 141.1 |  | 147.5 |
| 1 month | 141.1 | | 151.8 |
| Current year | 99.5 | | 158.5 |
| 1 year | 99.5 | | 158.5 |
| 3 years | 64.2 | | 158.5 |
| 5 years | 64.2 | | 255.4 |
| 10 years | 47.36 | | 255.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iqbal Ahmed
CEO | Chief Executive Officer | - | 03/03/2024 |
| Director of Finance/CFO | 63 | 31/12/2002 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 18/06/2009 | |
| Director/Board Member | - | 31/01/2010 | |
Iqbal Ahmed
BRD | Director/Board Member | - | 31/12/1984 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.55% | -1.02% | +10.94% | -0.82% | 526M | |
| -0.13% | -6.44% | +60.47% | +112.05% | 1,048B | |
| +0.85% | -0.81% | +52.77% | +63.15% | 640B | |
| -1.03% | -3.58% | +22.87% | +73.29% | 456B | |
| -1.46% | -4.50% | +37.43% | +38.41% | 362B | |
| -0.72% | -2.89% | +21.86% | +36.79% | 295B | |
| -1.19% | -2.21% | +1.35% | +12.29% | 255B | |
| -1.05% | -1.57% | +51.40% | +68.55% | 236B | |
| +0.08% | -1.78% | -17.64% | -54.29% | 204B | |
| -2.14% | -0.30% | +29.42% | +89.10% | 185B | |
| Average | -0.64% | -1.97% | +27.09% | +43.85% | 368.22B | |
| Weighted average by Cap. | -0.49% | -3.02% | +38.56% | +65.41% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 54.78B 445M 384M 360M 328M 619M 42.55B 621M 4.27B 1.67B 21.48B 1.67B 1.64B 71.23B | 60.95B 495M 427M 400M 365M 688M 47.35B 690M 4.75B 1.85B 23.9B 1.86B 1.82B 79.25B |
| Net income | 8.66B 70.4M 60.66M 56.88M 51.92M 97.81M 6.73B 98.12M 675M 263M 3.4B 264M 259M 11.26B | 9.52B 77.41M 66.7M 62.54M 57.09M 108M 7.4B 108M 742M 289M 3.73B 291M 284M 12.38B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/08/26 | BDT 145.00 | +0.55% | 512,040 |
| 25/08/26 | BDT 144.20 | +0.84% | 288,286 |
| 24/08/26 | BDT 143.00 | -0.83% | 390,247 |
| 23/08/26 | BDT 144.20 | -1.57% | 524,503 |
| 20/08/26 | BDT 146.50 | -0.34% | 449,897 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BXPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
